Disease Landscape and Forecast 인사이트

The moderate to severe ulcerative colitis (UC) drug market still offers substantial opportunity for companies that can address the remaining unmet needs in this patient population. The TNF-α…

For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine)…

Hyperphosphatemia is a common complication in the later stages of chronic kidney disease (CKD). Sequelae can include hypocalcemia, disturbances in bone mineralization homeostasis, and an increased…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia. Treatment goals…

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult CD, the primary goal of the treatment of pediatric CD is to…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Schizophrenia is an often disabling psychiatric disease that usually requires long-term treatment. The primary goals of medical treatment for schizophrenia are to reduce the frequency and severity…

Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved…

Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells (RBCs) that distorts them into a sickle shape. This sickling leads to…

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…

Rheumatoid arthritis (RA) patients refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF targeted therapy (e.g., Bristol-Myers Squibb’s…

Medicare beneficiaries with chronic obstructive pulmonary disease (COPD) have access to more than a dozen long-acting bronchodilator inhalers, ranging from blockbusters like GlaxoSmithKline’s (…